IN RE GTX, INC. SHAREHOLDERS LITIGATION

District Court, S.D. New York·Decided June 23, 2020·No. 1:19-cv-03239·Unknown

Opinion

DOCUMENT UNITED STATES DISTRICT COURT ELECTRONICALLY FILED SOUTHERN DISTRICT OF NEW YORK DOC #: IN RE GTX, INC. SHAREHOLDERS DATE FILED: 6/23/2020 LITIGATION 19 Civ. 3239 (AT) ORDER ANALISA TORRES, District Judge: Lead Plaintiffs, Nabil Barakat and Michael Cooper, on behalf of themselves and the pre- merger holders of the common stock of GTx, Inc. (“GTx”), bring this action against Defendants, GTx and its pre-merger Board of Directors, for their alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 in connection with GTx’s merger with Oncternal Therapeutics, Inc. (“Oncternal”). Compl. § 1, ECF No. 26. Now before the Court is Defendants’ motion to dismiss the complaint pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. ECF No. 52. For the reasons stated below, the motion is GRANTED. BACKGROUND The following facts are taken from the complaint and “are presumed to be true for purposes of considering a motion to dismiss for failure to state a claim.” Fin. Guar. Ins. Co. v. Putnam Advisory Co., LLC, 783 F.3d 395, 398 (2d Cir. 2015). Before its merger with Oncternal, GTx was a publicly-traded biopharmaceutical company dedicated to the development and commercialization of medicines to treat unmet medical conditions, including cancers. Compl. 24-25. Before the merger, Oncternal was a clinical-stage biopharmaceutical company, also focused on developing product candidates for treating cancers. Jd. 27. Until late 2018, GTx had been developing selective androgen receptor modulators (“SARM”) for cancer treatment. Jd. 24-26. In September 2018, however, GTx announced that a clinical trial (the “ASTRID Trial’) of its lead SARM product candidate, enobosarm, had

failed to achieve statistical significance and that its development would be discontinued. Id. ¶¶ 28–29.

Id. ¶ 30. Nevertheless, following the failure of the ASTRID Trial, GTx management began negotiating a possible sale of GTx’s technology or the company itself. Id. ¶¶ 31, 32. On March 6, 2019, GTx entered into a merger agreement with Oncternal. Id. ¶¶ 2, 34. That same day, GTx’s Id. ¶ 34.

Id. On March 7, 2019, GTx and Oncternal issued a joint press release announcing the merger

and stating that GTx shareholders would retain “an ownership interest representing approximately 25% of the outstanding shares of common stock of the combined company.” Id. ¶ 35. On April 8, 2019, Defendants filed a Form S-4 with the Securities and Exchange Commission (the “SEC”); the Form S-4 also served as a preliminary proxy statement for GTx shareholders, stating that GTx shareholders would receive approximately 25% of the combined company’s stock. Id. ¶ 36. On April 30, 2019, the merger agreement was amended such that Grizzly Merger Sub, Inc., a wholly-owned subsidiary of GTx, would merge with and into Oncternal, with Oncternal surviving as a wholly-owned subsidiary of GTx (the “Merger”). Compl. ¶¶ 2, 34. Compared to the originally proposed merger, the final Merger increased the exchange ratio1 from 0.4474 to 0.5137, reduced the portion of the combined company that GTx shareholders would purportedly retain from 25% to 22.5%, and devalued the non-transferable contingent value rights. Id. ¶ 37.

Id. ¶ 38. On May 7, 2019, Defendants filed their proxy statement (the “Proxy”2) with the SEC, pursuant to SEC Rule 424(b)(3), and on May 10, 2019, Defendants mailed the Proxy to GTx shareholders. Id. ¶ 39. The Proxy solicited GTx shareholders’ vote in favor of the Merger. Id. An introductory letter on the first page of the Proxy stated that GTx stockholders will “own[] approximately 22.5% of the outstanding capital stock of GTx” “as of immediately prior to the [e]ffective [t]ime” of the Merger, that this “exchange ratio formula excludes Oncternal’s outstanding stock options and warrants and GTx’s outstanding stock options and warrants,” and

that “[t]hese estimates are subject to adjustment prior to closing of the merger.” Id. ¶ 45. Similar language is repeated throughout the Proxy. See id. ¶¶ 46–49; see also id. ¶ 56 (“Immediately after the merger, . . . it is expected that . . . GTx’s existing stockholders [will] own[] approximately 22.5% of the outstanding capital stock of GTx.”). In the section titled “Risk Related to the Merger,” the Proxy stated that the approximate 22.5% / 77.5% “ownership percentages may be adjusted upward or downward based on cash levels of the respective

1 The “exchange ratio” is the relative number of new shares that will be given to existing shareholders of a company that has merged with another. See James Chen, Exchange Ratio Definition, Investopedia (Apr. 24, 2019), https://www.investopedia.com/terms/e/exchangeratio.asp. 2 The Proxy can be found on the SEC’s website. See https://www.sec.gov/Archives/edgar/data/1260990/000119312519139911/d722331d424b3.htm; see also ECF No. 55-1. companies at the closing of the [M]erger, and as a result, either GTx’s stockholders or the Oncternal stockholders could own less of the combined company than expected.” Id. ¶ 50. Similar language is repeated throughout the Proxy. See id. ¶¶ 51, 52, 58, 59. The Merger closed on June 7, 2019. Id. ¶ 41. Defendants announced the closing of the

Merger in a press release filed with the SEC in a Form 8-K, stating that pre-Merger GTx shareholders were “retaining an ownership interest representing approximately 22.5% of the outstanding shares of common stock of the combined company.” Id. ¶ 42. Plaintiffs, however, allege Id. ¶ 60.

Id. ¶ 63.

Id. ¶ 64.

Id. ¶ 66; see also id. ¶ 67

DISCUSSION

I. Legal Standard To survive a Rule 12(b)(6) motion to dismiss, a plaintiff must plead sufficient factual allegations in the complaint that, accepted as true, “state a claim to relief that is plausible on its face.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007) (internal quotation marks omitted)). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. A plaintiff is not required to provide “detailed factual allegations” in the complaint, but

must assert “more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do.” Twombly, 550 U.S. at 555. Ultimately, the facts pleaded in the complaint “must be enough to raise a right to relief above the speculative level.” Id. A court must “accept[] the factual allegations in the complaint as true, and draw[] all reasonable inferences in the plaintiff’s favor.” Chambers v. Time Warner, Inc., 282 F.3d 147, 152 (2d Cir. 2002). In evaluating the motion to dismiss, “the Court may consider documents that are referenced in the complaint, documents that the plaintiffs relied on in bringing suit and that are either in the plaintiffs’ possession or that the plaintiffs knew of when bringing suit, or matters of which judicial notice may be taken.” In re Bank of Am. AIG Disclosure Sec. Litig., 980 F. Supp.

2d 564, 570 (S.D.N.Y. 2013) (citing Chambers, 282 F.3d at 153). Accordingly, the Court will consider “public disclosure documents that must be filed with the . . . SEC,” id., including the Proxy. II. Analysis A.

Free access — add to your briefcase to read the full text and ask questions with AI

IN RE GTX, INC. SHAREHOLDERS LITIGATION, (S.D.N.Y. 2020).

IN RE GTX, INC. SHAREHOLDERS LITIGATION (IN RE GTX, INC. SHAREHOLDERS LITIGATION) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mills v. Electric Auto-Lite Co.
396 U.S. 375 (Supreme Court, 1970)
Virginia Bankshares, Inc. v. Sandberg
501 U.S. 1083 (Supreme Court, 1991)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
ATSI Communications, Inc. v. Shaar Fund, Ltd.
493 F.3d 87 (Second Circuit, 2007)
Howell v. Management Assistance, Inc.
519 F. Supp. 83 (S.D. New York, 1981)
Koppel v. 4987 Corp.
167 F.3d 125 (Second Circuit, 1999)
Grace v. Rosenstock
228 F.3d 40 (Second Circuit, 2000)
Chambers v. Time Warner, Inc.
282 F.3d 147 (Second Circuit, 2002)
Kocourek v. Shrader
391 F. Supp. 3d 308 (S.D. Illinois, 2019)
Horoshko v. Citibank, N.A.
373 F.3d 248 (Second Circuit, 2004)
Financial Guaranty Insurance v. Putnam Advisory Co.
783 F.3d 395 (Second Circuit, 2015)
Bond Opportunity Fund v. Unilab Corp.
87 F. App'x 772 (Second Circuit, 2004)
In re Bank of America AIG Disclosure Securities Litigation
980 F. Supp. 2d 564 (S.D. New York, 2013)